Sally Jacob
About Sally Jacob
Sally Jacob, Head of Communications
Sally Jacob currently holds the position of Head of Communications. She has 25 years of experience in the biopharmaceutical industry, specializing in corporate affairs and life sciences communications. Throughout her career, she has significantly contributed to various initiatives aimed at enhancing research transparency, compassionate use, clinical trials awareness, and public health education. Her collaboration with company leaders and patient organizations underscores her commitment to advancing the biopharmaceutical field.
Sally Jacob's Education and Expertise
Sally Jacob's academic accomplishments include an AB in history from Princeton University and an MA in English from Cornell University. This strong educational background has equipped her with essential skills for her roles in communications and corporate affairs. Her expertise is reflected in her ability to manage and execute comprehensive communication strategies within the biopharmaceutical sector.
Sally Jacob's Role in SpringWorks Therapeutics
Sally Jacob played a pivotal role in the Series A raise and launch of SpringWorks Therapeutics, a company spinout designed to develop and commercialize several Pfizer pipeline programs in rare diseases. Her leadership in communications was instrumental in the successful establishment of SpringWorks Therapeutics, marking a significant achievement in her career.
Sally Jacob's Experience at Amgen and Bristol-Myers Squibb
Prior to her current role, Sally Jacob led corporate brand communications for Amgen, where she developed and managed the company's brand strategies. Additionally, she has held various positions in Corporate Affairs at Bristol-Myers Squibb. These roles allowed her to gain a broad understanding of corporate communications within top-tier biopharmaceutical companies, further solidifying her expertise in the field.
Sally Jacob's Contributions to Corporate Communications
Throughout her 25-year career, Sally Jacob has collaborated with leaders in the biopharmaceutical industry, as well as research and patient organizations, to foster initiatives in research transparency, compassionate use programs, clinical trials awareness, and public health education. These efforts demonstrate her dedication to enhancing communication strategies that support both the scientific community and public health initiatives.